1,172 results on '"Copelan, Edward A."'
Search Results
102. Upper respiratory tract SARS-CoV-2 viral shedding in cancer patients.
103. Risk factors for hospitalization for cancer patients with SARS-CoV-2 infection.
104. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
105. Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee
106. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
107. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission
108. Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma
109. Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia
110. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR
111. Acute Myeloid Leukemia: When to Transplant in First Complete Remission
112. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia
113. Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?
114. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation
115. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
116. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy
117. Age no bar : A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
118. A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial
119. Hematopoietic Stem Cell Transplantation in Multiple Myeloma
120. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
121. Hematopoietic stem-cell transplantation
122. Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients
123. Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients
124. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
125. Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia
126. Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative
127. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
128. Hematopoietic Stem Cell Transplantation in Philadelphia-Positive Acute Lymphoblastic Leukemia
129. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation
130. A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission
131. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
132. Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
133. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
134. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
135. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
136. Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patients
137. Predicting Hematopoietic Stem Cell Mobilization Failure in Patients With Multiple Myeloma: A Simple Method Using Day 1 Cd34+ Cell Yield
138. 553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
139. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
140. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia
141. Improving the Odds
142. Levine Cancer Institute Approach to Pandemic Care of Patients With Cancer
143. Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).
144. Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy
145. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy
146. Impact of Weekend Admissions on Quality of Care and Outcomes in Patients With Acute Myeloid Leukemia
147. Navigating the nexus of MRD and novel agents in ALL
148. Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
149. Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
150. Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.